Accelerate your Oncology Research

The aggressive pace of oncology research is characterized by large-scale, multidisciplinary efforts such as The Cancer Genome Atlas, The Human Protein Atlas, and Precision Medicine Initiative. With a broader and deeper understanding of the biology and signaling pathways that lead to cancer, scientists are better equipped to identify, characterize, and target biomarkers that can be translated into clinical applications. However, with these recent advancements comes a desperate need to understand the influence of the tumor microenvironment on cancer progression, evolution, and the resulting immune response. To make this next leap forward, scientists need tools that enable them to take an integrated, multi-omic, and 360° view of the tumor, immune response and microenvironment.

Challenges

Novel single-cell cancer genomics studies and spatial biology have led to new insights on tumor heterogeneity. NanoString’s GeoMx Digital Spatial Profiling (DSP) technology allows for a thorough exploration of the complex interactions with the tumor microenvironment through visualization and quantification of transcripts and proteins on individual tissue sections.

Coupled with nCounter expression panels focused on clinical research, immuno-oncology, cancer metabolism, and CAR-T cell therapy, NanoString provides solutions for every step of the way in cancer research, from bulk gene expression analysis to spatial profiling.

NanoString offers solutions that overcome the biggest challenges in cancer research:

  • The complex interactions between the tumor and microenvironment
  • A highly heterogeneous disease that leads to variable therapeutic response
  • An ever-increasing number of possible therapeutic targets and combination trials

NanoString’s nCounter oncology gene expression panel portfolio has driven innovation since its inception, starting with the initial Hallmarks of Cancer Panel Collection and the best-selling PanCancer Immune Profiling Panel and PanCancer Pathways Panel. Expanding on this, the 360 Series Panel Collection and Data Analysis Service allow researchers to better understand therapeutic response/mechanism of action, immune evasion, and the interplay between the tumor and microenvironment.

Case Studies

Biomarkers for adjuvant
therapy predict benefit in early stage triple negative breast cancer

Read More
3d model of a cell

PanCancer IO 360
& GeoMx DSP Case Study – Pediatric Primary and Metastatic Osteosarcoma

Read More
Case Study

Related Resources

View All Resources
Blog Post From an Egyptian Papyrus to the Hallmarks of Cancer: A Journey through the Development of Knowledge in Oncology Research
Blog Post Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.
Blog Post Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog Post How the Field of Immuno-Oncology is Changing Fast
App Note/Tech Note Ultra-High-Plex Spatial Proteogenomics of FFPE Tissue Sections

Publications

View All Publications

Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens.

Glioblastoma is a heterogeneous tumor for which effective treatment options are limited and often insufficient. Few studies have examined the intratumoral transcriptional and proteomic heterogeneity of the glioblastoma microenvironment to characterize the spatial distribution of potential molecular and cellular therapeutic immunooncology targets.

PFKFB3 overexpression in monocytes of patients with colon but not rectal cancer programs pro-tumor macrophages and is indicative for higher risk of tumor relapse.

Introduction: Circulating monocytes are main source for tumor-associated macrophages (TAMs) that control tumor growth, angiogenesis, metastasis and therapy resistance. We raised the questions how monocyte programming is affected by growing tumors localized in colon and rectal sections, and how treatment onsets affect monocyte programming in the circulation.

Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors.

Background and aim: Only 10% of pancreatic ductal adenocarcinoma (PDAC) patients survive longer than five years. Factors underlining long-term survivorship in PDAC are not well understood.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us